

Table 1. Demographic and liver function characteristics of patients with COVID-19 based on the first case reports in three different countries.

Author, Year	Country	Age (years)	Sex	AST (IU/L)	ALT (IU/L)	COVID-19 Disease severity	Prior history of liver diseases	Drugs		
								<i>Antibiotic drugs</i>	<i>Antiviral drugs</i>	<i>Antifungal drugs</i>
Zhang YH, 2020 ⁶	China (Haikou)	3 months	Female	Normal	Normal	Non-severe	No	Azithromycin, Ceftazidime	Paramivir	NA
Chen F, 2020 ⁷	China (Wuhan)	1	Male	Normal	Normal	Severe	NA	Meropenem, Linezolid, Oseltamivir	NA	NA
Cai JH, 2020 ⁸	China (Shanghai)	7	Male	33	17	Non-severe	No	Levofloxacin	NA	NA
Holshue ML, 2020 ⁹	United States	35	Male	72 (16.4)*	124 (30.3)*	Non-severe	No	NA	NA	NA
Silverstein WK, 2020 ¹⁰	Canada	56	Male	NA	29	Non-severe	NA	NA	NA	NA

AST: aspartate aminotransferase. ALT: alanine aminotransferase. Liver diseases: any liver disease that can cause serum liver enzyme changes, such as viral hepatitis, autoimmune hepatitis, etc. NA: not available. Normal ranges for AST and ALT: AST < 40 IU/L and ALT < 40 IU/L.

*: Standard deviation of liver enzyme fluctuations during hospitalization